Literature DB >> 27475804

Immunotherapy as a Potential Treatment for Chordoma: a Review.

Shalin S Patel1, Joseph H Schwab2.   

Abstract

Chordoma is a locally aggressive primary malignancy of the axial skeleton. The gold standard for treatment is en bloc resection, with some centers now advocating for the use of radiation to help mitigate the risk of recurrence. Local recurrence is common, and salvaging local failures is quite difficult. Chemotherapy has been ineffective and small molecule targeted therapy has had only marginal benefits in small subsets of patients with rare tumor phenotypes or refractory disease. Recent successes utilizing immunotherapy in a variety of cancers has led to a resurgence of interest in modifying the host immune system to develop new ways to treat tumors. This review will discuss these studies and will highlight the early studies employing immune strategies for the treatment of chordoma.

Entities:  

Keywords:  Antigen processing; Bone tumors; CSPG4; CTLA-4; Carbon-ion; Chimeric antigen receptor; Chordoma; HLA; Immune checkpoint; Immune escape; Immune system; Immunotherapy; MHC; PD-1; PD-L1; PD-L2; Proton; Radiation; Radiotherapy; Sarcoma; Tumor antigen; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 27475804     DOI: 10.1007/s11912-016-0543-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  89 in total

Review 1.  Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.

Authors:  Chien-Chung Chang; Michael Campoli; Soldano Ferrone
Journal:  Adv Cancer Res       Date:  2005       Impact factor: 6.242

2.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

4.  Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas.

Authors:  Thomas F DeLaney; Norbert J Liebsch; Frank X Pedlow; Judith Adams; Elizabeth A Weyman; Beow Y Yeap; Nicolas Depauw; G Petur Nielsen; David C Harmon; Sam S Yoon; Yen-Lin Chen; Joseph H Schwab; Francis J Hornicek
Journal:  J Surg Oncol       Date:  2014-04-19       Impact factor: 3.454

5.  Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma.

Authors:  F J Tefany; R S Barnetson; G M Halliday; S W McCarthy; W H McCarthy
Journal:  J Invest Dermatol       Date:  1991-08       Impact factor: 8.551

6.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

7.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Authors:  Laura Senovilla; Erika Vacchelli; Jerome Galon; Sandy Adjemian; Alexander Eggermont; Wolf Hervé Fridman; Catherine Sautès-Fridman; Yuting Ma; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

View more
  4 in total

Review 1.  Advances in the management of primary bone sarcomas of the skull base.

Authors:  Idara Edem; Franco DeMonte; Shaan M Raza
Journal:  J Neurooncol       Date:  2020-04-18       Impact factor: 4.130

2.  Fingolimod inhibits proliferation and epithelial-mesenchymal transition in sacral chordoma by inactivating IL-6/STAT3 signalling.

Authors:  Jiaqi Wang; Wenhao Hu; Xiaowen Du; Ying Sun; Shuai Han; Guanjun Tu
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

3.  Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review.

Authors:  Shujing Liang; Jingxian Yang; Yun Lin; Tong Li; Wenrong Zhao; Jun Zhao; Chunyan Dong
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

4.  Lymphocyte-Related Inflammation and Immune-Based Scores Predict Prognosis of Chordoma Patients After Radical Resection.

Authors:  Wenhao Hu; Jiayi Yu; Yong Huang; Fanqi Hu; Xuesong Zhang; Yan Wang
Journal:  Transl Oncol       Date:  2018-02-22       Impact factor: 4.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.